Abstract
Diabetes mellitus affects more that 6% of the US population and its prevalence is increased by 30% in the last decade, dramatically in younger individuals. In fact, it kills more people annually than AIDS and breast cancer combined and when the long-term complications and their costs are considered, the implications of these numbers are sobering1. Although, good glycemic control can delay the development and progression of microvascular complications (retinopathy, nephropathy), such metabolic control is often difficult to achieve and to maintain and it is not yet clear whether the same is true for macrovascular complications, such as coronary heart disease, stroke2. In this regard, it is important to note that clinical studies show that diabetic patients treated with phenformin and tolbutamide3have lower blood glucose levels, but also an increased overall mortality and cardiovascular mortality. Thus, diabetic therapy should lead to a lower incidence of diabetic complications and, ultimately to lower mortality. The logical corollary to this question is which of the new treatment options will affect long-term diabetic mortality. In this contest, the correction of oxidative stress may have important implications in preventing diabetes-induced alterations, since one of the consequences of chronic hyperglycemia is enhanced oxidative stress3and reactive oxygen species have been implicated in the pathogenesis of many diabetic complications4.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Diabetes Surveillance Report, 2000, Atlanta, Ga: Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Center for Disease Control and Prevention..
UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS3). Lancet 352: 837–853.
Goldner. M G., Knattrud G.L., and Prout, T.E., 1971, Effect of hypoglycaemic agents on vascular complications in patients with adult onset diabetes. III Clinical Implications of UGDP results. JAMA 218: 1400–1410.
Baynes, J.W. and Thorpe, S.R., 1999, Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1–9.
Santini, S.A., Marra, G., Giardina, B., Cotroneo, P., Mordente, A., Martorana, G.E., Manto, A., and Ghirlanda G., 1997, Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46: 1853–1858.
Franconi, F., Bennardini, F., Mattana, A., Miceli, M., Ciuti, M. Mian, M., Gironi, A.,Bartolomei, G., Anichini, R., and Seghieri, G., 1995, Taurine deficiency in plasma and platelets of diabetic insulin-dependent patients: effects of taurine supplementation. Am. J. Clin. Nutr. 61: 1115–1119.
Kelly, G.S., 2000, Insulin resistance: lifestyle and nutritional interventions. Altern. Med. Rev. 5: 109–132.
Huxtable, R.J., 1992, Physiological actions of taurine. Physiol. Rev. 72: 101–163.
Hansen, A.H., 2001, The role of taurine in diabetes and the development of diabetic complications. Diab. Met. Res. Rev. 17: 330–346.
Devanmanoharan, C., Ali, P.S., and Varna, A.H., 1997, Prevention of lens protein glycation by taurine Mol. Cell Biochem. 177: 245–250.
Di Leo, M.A.S., Santini, S.A, Cercone, S., Marra, G., Lepore, D., Caputo, S., Antico, L., Giardina, B., Pitocco, D., Franconi, F., and Ghirlanda, G., 1999, Dose-dependent effects of taurine in the prevention of Na, K-ATPase impairment and lipid peroxidation in the retina of streptozotocin-diabetic rats. Diabetologia 42 (Suppl. 1): A315.
Di Leo, M.A.S., Santini, S.A., Cercone, S., Lepore, D., Gentiloni Silveri, N., Caputo, S., Greco, A.V., Giardina, B., Franconi, F., and Ghirlanda, G., 2002, Chronic taurine supplementation ameliorates oxidative stress and Na`K’ATPase impairment in the retina of diabetic rats. Amino Acids in press.
Obrosova, 1., Minchenko, A.G., Marinescu, V., Fathallah, L., Kennedy, A., Stockert, C.M., Frank, R.N., and Stevens, M.J., 2001, Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rat. Diabetologia 44:1102–1110.
De Luca, G., Calpona, P.R., Caponetti, A., Romano, G., Di Benedetto, A., Cucinotta, D., and rgio R.M., 2001, Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetes. Metabolism 50: 60–64.
Nakamura, T., Ushiyama, C., Suzuki, S., Shimada, N., Ohmuro, H., Ebihara, I., and Koide, H., 1999, Effects of taurine and vitamin E on microalbuminuria, plasma metallo proteinase-9, and serum type IV collagen concentrations in patients with diabetic nephropathy. Nephron 83: 361–362.
Neuzil, J., Weber, C., and Kontush A., 2001, The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. Atherogenesis 157: 257–283.
van Dam, P.S., Bravenboer, B., van Asbeck, BS, Marx, J.J.S., and Gispen, W.H., 1999, High rat food vitamin E content improves nerve function in streptozotocin-diabetes rat. Eur. J. Pharmacol. 376: 217–222.
Faure, P., Rossini, E., Lafond, J.L., Favier, R.M.J., and Halimi, S., 1977,X Vitamin E improves the free radicals defense system potential and insulin sensitivity of rats fed high fructose diets. J. Nutr 127: 103–107.
Douillet, A., Tabib, M., Bost, M., Accominotti, F., Borson-Chazot R., and Ciavatti, M., 1996, A selenium supplement associated or not with vitamin E delay early renal lesions in experimental diabetes in rats. Proc. Soc. Exp. Biol. Med. 211: 323–331.
Matz, R., 1998, Sulfonylureas and ischemic heart disease Arch. Intern. Med. 158: 411–412.
Heart Protection Study Collaborative Group, 2002, MRC/BHF heart protection study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo controlled trial. Lancet 360: 23–33.
Wagner, A.M., Martinez-Rubio, A., Ordonez-Llanos, J., and Perez-Perez, A., 2002, XDiabetes mellitus and cardiovascular disease. Eur. J. Intern. Med. 13: 15–30.
Laasko, M., and Letho, S., 1997, Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 5, 294–310.
Militante, J.D., Lombardini, J.B., and Schaffer, S.W., 2000, The role of taurine in the pathogenesis of the cardiomyopathy of insulin-dependent diabetes. Cardiovascular Res. 393: 393–400.
Franconi, F., Stendardi, I., Failli, P., Matucci, R., Baccaro, C., Montorsi, L., Bandinelli, R., and Giotti, A., 1985, The protective effects of taurine on hypoxia (performed in the absence of glucose) and on reoxygenation (in the presence of glucose) in guinea-pig heart. Biochem. Pharmacol. 34: 2611–2614.
Takahashi, K., Ohyabu, Y., Schaffer, S.W., and Azuma J., 2000, Taurine prevents ischemia damage in cultured neonatal rat cardiomyocytes. Adv. Exp. Med. Biol. 483:109–116.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Franconi, F. et al. (2003). Taurine Reduces Mortality in Diabetic Rats. In: Lombardini, J.B., Schaffer, S.W., Azuma, J. (eds) Taurine 5. Advances in Experimental Medicine and Biology, vol 526. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0077-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0077-3_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4913-6
Online ISBN: 978-1-4615-0077-3
eBook Packages: Springer Book Archive